| Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. | |
| | |
MedLine Citation:
|
PMID: 21061833 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Hypertension is a widely prevalent condition of elevated blood pressure (BP) and is the leading risk factor for the development of cardiovascular disease (CVD). Many patients have additional risk factors such as diabetes mellitus (DM) or previous history of CVD. Nebivolol is a third-generation beta (beta)-blockers which has been shown not to influence metabolic parameters in patients with DM. This postmarketing surveillance study aimed to collect information on the efficacy, safety and tolerability of nebivolol in hypertensive patients with concomitant DM. PATIENTS AND METHODS: Hypertensive patients with DM followed by 52 cardiologists, internal medicine specialists and general practitioners, between 24 August 2003 and 9 January 2007 in The Netherlands were included in this study. Physicians were asked to survey nebivolol treatment for 6 months. RESULTS: A total of 510 patients were enrolled. Overall, 93.3% of patients were diagnosed with essential hypertension and 6.7% with secondary hypertension. All patients were co-diagnosed with DM. Nebivolol therapy was associated with a significant reduction in both systolic blood pressure (BP) and diastolic BP versus baseline (p < 0.001 for both). These reductions were seen regardless of reason for initiation of nebivolol (i.e. first diagnosis of hypertension, resistance or intolerance to previous antihypertensive medication, or other reasons). A significant improvement in blood glucose was seen at 4 months (-0.6 mmol/L; p = 0.021). Significant reductions in total cholesterol (-1.45 mmol/L; p = 0.006), low density lipoprotein (LDL) cholesterol (-1.32 mmol/L; p = 0.003) and LDL/high density lipoprotein (HDL) cholesterol ratio (-0.77; p = 0.011) were observed at 2 months. No significant changes were seen in HDL cholesterol and triglycerides. CONCLUSION: Nebivolol treatment was associated with a significantly reduced BP, improved blood glucose and LDL cholesterol levels and was well tolerated in hypertensive patients with concomitant DM. |
| | |
Authors:
|
L M Van Bortel |
Related Documents
:
|
2564723 - The effects of terazosin and methyclothiazide on blood pressure and serum lipids. 8466723 - Calcium antagonists and atherosclerosis. the multicenter isradipine/diuretic atheroscle... 9662483 - Heart rate control of blood pressure variability in children: a study in subjects with ... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European review for medical and pharmacological sciences Volume: 14 ISSN: 1128-3602 ISO Abbreviation: Eur Rev Med Pharmacol Sci Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-11-10 Completed Date: 2010-12-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9717360 Medline TA: Eur Rev Med Pharmacol Sci Country: Italy |
Other Details:
|
Languages: eng Pagination: 749-58 Citation Subset: IM |
Affiliation:
|
Clinical Pharmacology, Heymans Institute of Pharmacology, Ghent University, Gent, Belgium. luc.vanbortel@UGent.be |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Analgesics / adverse effects, therapeutic use* Benzopyrans / adverse effects, therapeutic use* Blood Glucose / metabolism Blood Pressure / drug effects* Cholesterol / blood Diabetes Mellitus* / blood, physiopathology Ethanolamines / adverse effects, therapeutic use* Female Humans Hypertension / blood, complications, drug therapy*, physiopathology Male Medication Adherence Middle Aged Netherlands Product Surveillance, Postmarketing Prospective Studies Time Factors Treatment Outcome Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Analgesics; 0/Benzopyrans; 0/Blood Glucose; 0/Ethanolamines; 0/Triglycerides; 57-88-5/Cholesterol; 99200-09-6/nebivolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Screening of extracts of algae from Baja California sur, Mexico as reversers of the antibiotic resis...
Next Document: Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women...